Chiasma Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
73,134.20
13,165.80
-
-
-
88
Cost of Goods Sold (COGS) incl. D&A
-
-
201.00
433.00
152.00
88
Gross Income
-
-
201.00
433.00
152.00
88
SG&A Expense
32,351.70
14,009.60
35,092.00
52,699.00
26,942.00
32,248
EBIT
40,460.90
1,115.80
35,293.00
53,132.00
27,094.00
32,336
Unusual Expense
1,907.20
714.70
154.00
8,179.00
1,038.00
-
Non Operating Income/Expense
87.20
19.70
79.00
9.00
212.00
31
Interest Expense
1,065.70
26.60
349.00
264.00
-
-
Pretax Income
37,405.50
1,834.90
35,747.00
60,764.00
27,416.00
31,292
Income Tax
1,224.40
175.60
161.00
347.00
590.00
31
Consolidated Net Income
36,181.00
2,010.50
35,908.00
61,111.00
26,826.00
31,261
Net Income
36,181.00
2,010.50
35,908.00
61,111.00
26,826.00
31,261
Net Income After Extraordinaries
36,181.00
2,010.50
35,908.00
61,111.00
26,826.00
31,261
Net Income Available to Common
5,357.50
2,914.60
36,226.00
61,111.00
26,826.00
31,261
EPS (Basic)
0.22
0.12
3.25
2.51
1.10
1.28
Basic Shares Outstanding
23,929.40
23,929.40
11,152.00
24,319.40
24,366.70
24,399.70
EPS (Diluted)
0.22
0.12
3.25
2.51
1.10
1.28
Diluted Shares Outstanding
23,929.40
23,929.40
11,152.00
24,319.40
24,366.70
24,399.70
EBITDA
40,782.50
843.80
35,092.00
52,699.00
26,942.00
32,248
Non-Operating Interest Income
4.50
2.50
128.00
802.00
928.00
1,013
Preferred Dividends
41,538.60
904.00
318.00
-
-
-

About Chiasma

View Profile
Address
460 Totten Pond Road
Waltham Massachusetts 02451
United States
Employees -
Website http://www.chiasmapharma.com
Updated 07/08/2019
Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The company's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications.